A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Eya3 promotes breast tumor–associated immune suppression via threonine phosphatase–mediated PD-L1 upregulation
2018
Journal of Clinical Investigation
at a static time point, we tested whether there was a significant difference between SCR versus Eya3 KD2 and KD3. This was done using an ANOVA by comparing the effect of SCR against the average effect of KD2 and KD3 (done using sum contrasts in R) and the corresponding P value was reported. All graphs were created using GraphPad Prism software. If exact P values were not stated, reported P values are as follows: *P < 0.05, **P < 0.01, ***P < 0.001. Study approval. All animal studies were
doi:10.1172/jci96784
pmid:29757193
fatcat:7asjdqc3lfcu7f6qxd7xvigjha